Show simple item record

dc.contributor.authorNúñez Gil, Ivan J
dc.contributor.authorElizondo, Ainhoa
dc.contributor.authorGradari, Simona
dc.contributor.authorVillablanca, Pedro A
dc.contributor.authorBueno, Héctor 
dc.contributor.authorFeltes, Gisela
dc.contributor.authorQuirós, Alicia
dc.contributor.authorRamakrishna, Harish
dc.contributor.authorBoshra, Louka
dc.contributor.authorFernandez-Ortiz, Antonio
dc.identifier.citationCardiovasc Revasc Med. 2019; 20(10):897-906es_ES
dc.description.abstractTherapeutic strategies - such as duration of dual antiplatelet therapy after coronary artery stenting - usually generate a large quantity of meta-analyses. The meta-analyses that include the same randomized clinical trials should produce similar results. Our aim in the study is to analyze the quality and to compare the results of meta-analyses focused on a controversial topic such as dual antiplatelet therapy after percutaneous coronary intervention. We searched all published meta-analyses published up to November 2015 (near DAPT trial publication) selecting those that included the same randomized clinical trials comparing patterns of briefer versus longer-term double antiplatelet therapy. Seventeen meta-analyses achieved our selection criteria. Of the seventeen analyzed, we identified seven (41.1%) based on the same ten randomized clinical trials (RCTs), yet their results varied widely. Many of the meta-analyses differed in only some minor aspect of the design (i.e. eligible studies, length of comparators and statistical methods used). Some authors differed in the number of patients participating in RCTs and even, despite reviewing the same underlying trials, only 2 of the 7 meta-analyses included the same number of patients. Meta-analyses around cardiovascular, all-cause or non-cardiovascular death differ frequently. In the DAPT duration setting, several meta-analyses have been recently published based on the same data, presenting several issues making it difficult to determine clear recommendations on certain points.es_ES
dc.description.sponsorshipIN receives research funding from Astrazeneca; has received minor consulting fees from Boston, Medtronic, Astrazeneca; and speaking fees or support for attending scientificmeetings fromBoehringer, Daiichi-Sankyo, Lilly, AstraZeneca and Pfizer. AE is Astrazeneca employee. HB receives research funding from the Instituto de Salud Carlos III (PIE16/00021), AstraZeneca, BMS, Janssen and Novartis; has received consulting fees from Abbott, AstraZeneca, Bayer, BMS-Pfizer, Novartis; and speaking fees or support for attending scientificmeetings from AstraZeneca, Bayer, BMS-Pfizer, Ferrer, Novartis, Servier and MEDSCAPE-the heart.og. The other authors pose no relevant disclosures regarding this manuscript.es_ES
dc.subject.meshMeta-Analysis as Topic es_ES
dc.subject.meshPercutaneous Coronary Intervention es_ES
dc.subject.meshRandomized Controlled Trials as Topic es_ES
dc.subject.meshResearch Design es_ES
dc.subject.meshCoronary Artery Disease es_ES
dc.subject.meshData Accuracy es_ES
dc.subject.meshDrug Therapy, Combination es_ES
dc.subject.meshHumans es_ES
dc.subject.meshPlatelet Aggregation Inhibitors es_ES
dc.subject.meshRisk Factors es_ES
dc.subject.meshTreatment Outcome es_ES
dc.titleMeta-Analysis Design and Results in Real Life: Problem Solvers or Detour to Maze. A Critical Review of Meta-Analysis of DAPT Randomized Controlled Trials.es_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.contributor.funderFundación AstraZeneca
dc.contributor.funderInstituto de Salud Carlos III - ISCIII
dc.identifier.journalCardiovascular revascularization medicine : including molecular interventionses_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Investigación Cardiovascular Traslacional Multidisciplinariaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Imagen Cardiovascular y Estudios Poblacionaleses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This item is licensed under a: Attribution-NonCommercial-NoDerivatives 4.0 Internacional